亚砷酸注射液对大肠癌患者无进展生存期及相关细胞因子的影响
|
摘要
[目的]探讨亚砷酸注射液对大肠癌术后化疗后患者无进展生存期及相关细胞因子的影响。[方法]将64例大肠癌术后化疗后患者分为对照组和观察组,每组各32例。对照组为定期复查患者,观察组应用亚砷酸注射液间断巩固治疗。于疗程结束后记录患者无进展生存期(progression-free survival,PFS)和生存率,及体内相关细胞因子血清基质金属蛋白酶2(MMP-2)、基质金属蛋白酶9(MMP-9)、肿瘤坏死因子-α(TNF-α)及血管内皮生长因子(VEGF)的表达水平。[结果]观察组PFS(20.4±2.9)个月显著长于对照组(12.3±2.1)个月(P<0.05);观察组生存率为85.27%显著高于对照组的61.74%(P <0.05);观察组血清相关细胞因子(MMP-2、MMP-9、TNF-α、VEGF)表达水平显著低于对照组(P<0.05)。[结论]应用亚砷酸注射液间断巩固治疗可以显著抑制体内肿瘤相关细胞因子指标表达,减低肿瘤复发可能,延长大肠癌患者无进展生存期并提高生存率。
[Objective]To investigate the effect of arsenic trioxide on progression-free survival time and related cytokines in post-operation colorectal cancer patients after chemotherapy.[Methods]64cases of colorectal cancer patients were divided into control group and observation group,with 32 cases in each group.The control group patients received review regularly,observation group was treated with arsenic trioxide intermittently for consolidation treatment.PFS,survival rate and cytokines including MMP-2,MMP-9,TNF-α,VEGF were recorded after treatment.[Results]The PFS of the observation group(20.4±2.9)was significantly longer than that of the control group(12.3±2.1)(P<0.05).The survival rate of the observation group(85.27%)was significantly higher than that of the control group(61.74%)(P<0.05).The level of cytokines in observation group was significantly lower than that of the control group(P<0.05).[Conclusion]the intermittent application of arsenic trioxide in consolidation treatment of colorectal cancer patients could inhibit the expression of cancer-associated cytokines,reduce cancer recurrence,prolong the PFS and improve survival rate.
[Objective]To investigate the effect of arsenic trioxide on progression-free survival time and related cytokines in post-operation colorectal cancer patients after chemotherapy.[Methods]64cases of colorectal cancer patients were divided into control group and observation group,with 32 cases in each group.The control group patients received review regularly,observation group was treated with arsenic trioxide intermittently for consolidation treatment.PFS,survival rate and cytokines including MMP-2,MMP-9,TNF-α,VEGF were recorded after treatment.[Results]The PFS of the observation group(20.4±2.9)was significantly longer than that of the control group(12.3±2.1)(P<0.05).The survival rate of the observation group(85.27%)was significantly higher than that of the control group(61.74%)(P<0.05).The level of cytokines in observation group was significantly lower than that of the control group(P<0.05).[Conclusion]the intermittent application of arsenic trioxide in consolidation treatment of colorectal cancer patients could inhibit the expression of cancer-associated cytokines,reduce cancer recurrence,prolong the PFS and improve survival rate.
引文
[1]王磊,宋顺心,汪建平,等.结直肠癌实验研究现状及展望[J].中华实验外科杂志,2013,30(3):429-430.
[2] Van Cutsem E,Costa F.Progress in the adjuvant treatment of colon cancer:has it influenced clinical practice[J].JAMA,2005,294(21):2758-2760.
[3]程悦蕾,朱惠蓉,张卓.中医药治疗大肠癌及其术后患者的临床研究进展[J].中华中医药学刊,2014,32(9):2219-2224.
[4]卢壁辉,黄壮生.MMP-7、VEGF-C和VEGFR-3在结肠癌组织中的表达及相关性[J].广东医学,2015,36(6):878-880.
[5] Bhatti I,Patel M,Dennison AR,et al.Utility of postoperative CEA for surveillance of recurrence after resection of primary colorectal cancer[J].Int J Surg,2015,16(Pt A):123-128.
[6]李玉明,李东芳,王云启.中药联合化疗治疗对大肠癌患者CEA、CD3及CD8水平表达的影响[J].实用癌症杂志,2016,31(11):1909.
[7]张明林,许建明,梅俏,等.MMP2、MMP9蛋白在结肠癌中的表达[J].世界华人消化杂志,2005,13(20):2494-2497.
[8]伍尚标,陈戎,苏榕,等.结肠癌患者血清VEGF、CEA和CRP联合检测的临床意义[J].实用医学杂志,2011,27(13):2393-2394.
[9]李娜,唐艳,刘翠兰,等.VEGF及TNF-α在大肠癌中的表达及临床意义[J].中国医药指南,2012,10(17):176-178.
[10]胡晓晨,李金梅,张春,等.713注射液治疗急性早幼粒细胞白血病的临床研究[J].中医药学报,1996,2(12):18-19.
[11]胡晓晨,李金梅,张春,等.亚砷酸注射液治疗急性早幼粒细胞白血病244例临床与实验研究[A].世界中西医结合大会论文摘要集[C].1997年.
[12]胡晓晨,张春,胡鸣旭.亚砷酸注射液治疗复发性急性早幼粒细胞白血病临床研究[A].全国中西医结合血液病学术研讨会、浙江省中西医结合学会血液病专业委员会成立大会首次学术年会暨继续教育学习班论文汇编[C].2006年.
[13]Yi Y.Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway[J].Cancer Biol Therapy,2010,10(3):251-257.
[14]隋室铭.三氧化二砷诱导的结肠癌细胞凋亡及其与细胞周期的关系[J].癌症,2000,10(2):120.
[15]秦叔逵,陈洪,陈惠英,等.三氧化二砷诱导人肝癌细胞株凋亡的初步研究[J].临床肿瘤学杂志,1998,3(2):40.
[16]Zhang TC,Cao FH,Li JF Induction of apoptosis and Inhibition of human gastric cancer MGC803 cell growth by arsenic trioxide[J].Eur J Cancer,1999,35(8):1258-1263.
[2] Van Cutsem E,Costa F.Progress in the adjuvant treatment of colon cancer:has it influenced clinical practice[J].JAMA,2005,294(21):2758-2760.
[3]程悦蕾,朱惠蓉,张卓.中医药治疗大肠癌及其术后患者的临床研究进展[J].中华中医药学刊,2014,32(9):2219-2224.
[4]卢壁辉,黄壮生.MMP-7、VEGF-C和VEGFR-3在结肠癌组织中的表达及相关性[J].广东医学,2015,36(6):878-880.
[5] Bhatti I,Patel M,Dennison AR,et al.Utility of postoperative CEA for surveillance of recurrence after resection of primary colorectal cancer[J].Int J Surg,2015,16(Pt A):123-128.
[6]李玉明,李东芳,王云启.中药联合化疗治疗对大肠癌患者CEA、CD3及CD8水平表达的影响[J].实用癌症杂志,2016,31(11):1909.
[7]张明林,许建明,梅俏,等.MMP2、MMP9蛋白在结肠癌中的表达[J].世界华人消化杂志,2005,13(20):2494-2497.
[8]伍尚标,陈戎,苏榕,等.结肠癌患者血清VEGF、CEA和CRP联合检测的临床意义[J].实用医学杂志,2011,27(13):2393-2394.
[9]李娜,唐艳,刘翠兰,等.VEGF及TNF-α在大肠癌中的表达及临床意义[J].中国医药指南,2012,10(17):176-178.
[10]胡晓晨,李金梅,张春,等.713注射液治疗急性早幼粒细胞白血病的临床研究[J].中医药学报,1996,2(12):18-19.
[11]胡晓晨,李金梅,张春,等.亚砷酸注射液治疗急性早幼粒细胞白血病244例临床与实验研究[A].世界中西医结合大会论文摘要集[C].1997年.
[12]胡晓晨,张春,胡鸣旭.亚砷酸注射液治疗复发性急性早幼粒细胞白血病临床研究[A].全国中西医结合血液病学术研讨会、浙江省中西医结合学会血液病专业委员会成立大会首次学术年会暨继续教育学习班论文汇编[C].2006年.
[13]Yi Y.Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway[J].Cancer Biol Therapy,2010,10(3):251-257.
[14]隋室铭.三氧化二砷诱导的结肠癌细胞凋亡及其与细胞周期的关系[J].癌症,2000,10(2):120.
[15]秦叔逵,陈洪,陈惠英,等.三氧化二砷诱导人肝癌细胞株凋亡的初步研究[J].临床肿瘤学杂志,1998,3(2):40.
[16]Zhang TC,Cao FH,Li JF Induction of apoptosis and Inhibition of human gastric cancer MGC803 cell growth by arsenic trioxide[J].Eur J Cancer,1999,35(8):1258-1263.